Adimab LLC’s tech transfer deals with GlaxoSmithKline PLC and Biogen Inc. represent the small biotech’s greatest business development and financial successes to date, and confirm that with the right technology, it’s possible to build a successful and rapidly profitable company whose own ambitions begin and end at drug discovery.
Adimab Discovers Sustainable Profitability Through GSK, Biogen Deals
The antibody engineering company Adimab LLC has signed two non-exclusive deals that should put the small biotech firmly in the black. The deals with GSK and Biogen, announced July 26, are Adimab’s first in which it transfers its technology for broad use by partners.
More from Archive
More from Pink Sheet
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.